Podcast: An Innovative Approach to Treating Multi-Drug Resistant Bacterial Infections

Company to Watch – Venatorx Pharmaceuticals


As part of May’s Company to Watch program, we spoke to Christopher Burns, founder, president, and CEO of Venatorx, about the need for new means of combating multi-drug resistant microbes, the company’s combination therapies in development, and its success at advancing its pipeline with non-dilutive funding.